STVN Stock Analysis: Buy, Sell, or Hold?
STVN - Stevanato Group S.p.A.
$15.58
-0.42 (-2.62%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 05, 2026
Get Alerted When STVN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: STVN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: STVN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$33.04
Based on 12.5% avg growth
INTRINSIC VALUE TODAY
$20.52
24.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: STVN is currently trading at $15.58, which is considered oversold relative to its 30-day fair value range of $17.71 to $21.48. From a valuation perspective, the stock is trading at a discount (Forward PE: 21.1) compared to its historical average (27.9). Remarkably, the market is currently pricing in an annual earnings decline of 8.9% over the next few years. This pessimistic expectation contrasts with the company's recent 18.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, STVN is in a strong downtrend. The price is currently testing key support at $15.28. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $28.69 (+84.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, STVN is in a strong downtrend. The price is currently testing key support at $15.28. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $28.69 (+84.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$17.71 -
$21.48
Company Quality Score
57/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
77.7%
Protect Your Profits
Holding STVN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 84.1% below Wall St target ($28.69)
- CAUTION: Recommendation downgraded due to -9.8% 5-day decline
Fair Price Analysis
30-Day Fair Range
$17.71 -
$21.48
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$2.01
(12.9%)
Support & Resistance Levels
Support Level
$15.28
Resistance Level
$21.16
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
21.09
Wall Street Target
$28.69
(+84.1%)
Revenue Growth (YoY)
9.1%
Earnings Growth (YoY)
18.2%
Profit Margin
12.0%
Valuation Discount vs History
-8.9% cheaper
PE vs Historical
21.1 vs 27.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.9%
(market-implied from PE analysis)
1-Year Target
$14.19
(-9%)
2-Year Target
$12.93
(-17%)
3-Year Target
$11.78
(-24%)
3-Yr Target (if PE normalizes)
(PE: 21→28)
$15.58
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 21.0%)
$29.15
(+87%)
Base:
(SPY PE: 21.1, Growth: 21.0%)
$27.57
(+77%)
Bear:
(PE: 17.9, Growth: 21.0%)
$23.44
(+50%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Trailing PE: 26.26 | Current EPS (TTM): $0.61
Bull Case
$21.35
(+37%)
Analyst growth 21.1%, PE expands to 28.9
Base Case
$19.41
(+25%)
Market implied 21.1%, PE stable at 26.3
Bear Case
$10.89
(-30%)
Severe decline -20.0%, PE contracts to 22.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.1 to 27.9
Stabilization Target:
$20.61
(+32.3%)
PE Expansion Potential:
+32.3%
Last updated: February 01, 2026 9:55 AM ET
Data refreshes hourly during market hours. Next update: 10:55 AM
Data refreshes hourly during market hours. Next update: 10:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is STVN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$92 | 63 BUY |
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$612 | 58 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$191 | 58 HOLD |
|
RMD
ResMed Inc |
BUY
19 analysts |
$297 | 57 HOLD |
|
ALGN
Align Technology Inc |
BUY
18 analysts |
$184 | 62 BUY |
Advanced STVN Option Strategies
Professional options setups generated by AI based on today's STVN price and gamma walls.
